cfn is pleased to announce that it has partnered with age-well, perley health and sepsis canada to co-fund early career researchers (ecrs) in canada. this competition will help ecrs build skills, knowledge and allow them to develop early stage research programs such that they are competitive for future larger funding competitions.

partnership engage grants are expected to respond to the objectives of the insight program and the connection program. however, partnership engage grants cannot respond exclusively to the objectives of the connection program.

these grants provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector. the small-scale, stakeholder-driven partnerships supported through partnership engage grants are meant to respond to immediate needs and time constraints facing organizations in non-academic sectors. in addressing an organization-specific need, challenge and/or opportunity, these partnerships let non-academic organizations and postsecondary researchers access each other’s unique knowledge, expertise and capabilities on topics of mutual interest.

sshrc welcomes applications involving indigenous research, as well as those involving research-creation.

the overarching goal of this funding program is to accelerate the application of high-quality evidence that is meaningful to people affected by cancer in the near term (i.e. 2-5 years).

through ccs accelerator grants, we will support research that addresses one of the following: 

• ·       synthesis grants: applications that aim to synthesize existing evidence (both qualitative and quantitative) to conclusively identify unmet cancer-related needs, identify research gaps, or to pool existing evidence to determine implementation strategy effectiveness. the expectation is that funded syntheses would contribute to informing decisions about programs, procedures, practices, or policies that will be meaningful to people affected by cancer. 
• ·       implementation science grants: applications that aim to identify, assess, develop and evaluate strategies that can influence the adoption, implementation and sustainment of validated, efficacious, reproducible, and needed evidence-based interventions - including programs, practice guidelines and policies) (or conversely, de-implementation of ineffective, contradicted, mixed, and untested (i.e. potentially harmful) health interventions) that will be meaningful to people affected by cancer.

important dates:

• ·       abstract registrations due: may 25, 2022
• ·       notification of relevance results: june 2, 2022
• ·       full applications due: july 20, 2022
• ·       results announcement: october 2022
• ·       anticipated start date: october 15, 2022

funding will be available for: 

• ·       up to $100k per synthesis grant over 1-2 yrs (max $50k/yr)  
• ·       up to $200k per implementation science grant over 1-2 yrs (max $100k/yr)  
• ·       approximately $1.6m in total may be awarded in this funding envelope

view the full funding opportunity here.

the eureka smart cluster has launched its 5th call for proposals for research, development and innovation (r&d&i) projects.

smart is a flexible, industry-driven eureka cluster program whose aim is to promote collaborative, international, and close-to-market r&d&i projects in advanced manufacturing.

•  please contact jill sherman, international research facilitator, if this opportunity is of interest at intl.research@lakeheadu.ca

the fy22 defense appropriations act provides funding for the tbdrp to support innovative, high-impact tick-borne disease research.  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 tbdrp funding opportunity announcements for the following award mechanisms is posted on the grants.gov website. 

applicants to the fy22 tbdrp funding opportunities must be relevant to at least one of the following focus areas.  applicants are particularly encouraged to submit applications focused on tick-borne diseases (tbds) and conditions endemic to the u.s., and/or involving patients with persistent lyme disease.  the proposed research must be focused on directly impacting human health and diseases/conditions that affect the u.s. military (active duty or veteran), their beneficiaries, or the american public. 

• ·        prevention (idea development award only)

○       drugs, antibodies, vaccines, or other novel approaches that can be administered and/or utilized prophylactically to prevent human tbds and conditions prevalent in the u.s. or that address multiple pathogens

○       identification, validation, and/or improvement of tick- or reservoir-targeted prevention and control interventions that are safe and non-toxic to non-target species

• ·        pathogenesis (idea development award only)

○       pathogenesis of persistent clinical manifestations associated with lyme disease

○       immune evasion and/or tolerance of tick-borne (tb) pathogens (lyme and/or other tbds)

○       tb infections and co-infections (simultaneous or sequential) and their effects on human disease severity, the local and systemic immune response, or pathogen synergy and competition

○       pathogenesis of mammalian meat allergy (allergic response to galactose-alpha-1,3-galactose [alpha gal])

○       understanding the role of tbds on maternal health and adverse birth outcomes, including maternal-fetal transmission

• ·        treatment (therapeutic/diagnostic idea award only)

○       novel preclinical therapeutic strategies for tb pathogens, lyme disease, and/or other tbds with priority given to those in the u.s.

§  potential treatments designed to mitigate development of long-term sequelae following infection

§  repurposing food and drug administration (fda)-approved drugs for off-label indication in preclinical evaluation for use in tbds

• ·        diagnosis (therapeutic/diagnostic idea award only)

○       priority given to development of direct detection diagnostic assays for agents of lyme disease and/or other tbds

○       diagnostic biomarker panel for lyme disease and/or other tbds that distinguishes tb infection from other febrile illnesses

○       approaches capable of distinguishing active infection and previous exposure and/or monitoring response to treatment

○       innovative approaches that provide diagnosis for a single or multiple tb infections

funding opportunities-fy22 tbdrp, congressionally directed medical research programs (cdmrp) (army.mil)

idea development award (ida) – preproposal due may 26, 2022

ida: 

independent investigators at or above the level of assistant professor (or equivalent)

ida – career development option:

• ·     principal investigator (pi) – investigators within 10 years of completing terminal degree at the time of application submission, working to become an independent investigator in tbd research.
• ·     mentor – independent investigators at or above the level of associate professor (or equivalent); must be an experienced tbd researcher as demonstrated by a recent history of funding and publications in tbd research, specifically in the field of the proposed studies.
• ·     mentorship is required.  the pi and mentor may be at different organizations.
• ·        prevention and pathogenesis focus areas only.
• ·        supports research that could lead to impactful discoveries or significant advancements that will accelerate progress toward reducing the burden of lyme disease and/or other tick-borne diseases (tbds) and conditions, and improving patient care and/or quality of life.
• ·        research should be conceptually innovative, exhibit high levels of creativity, or challenge existing research paradigms.
• ·        applications must describe the short- and long-term impact of the proposed research, as well as the public health burden of the diseases being addressed.
• ·        the career development option is intended to fund early-career investigators to conduct impactful research under the mentorship of an experienced tbd researcher. applications submitted under this option will be reviewed via separate, career development-specific evaluation criteria by a separate, dedicated peer review panel.
• ·        preliminary data is required, unless submitting under the career development option.
• ·        clinical trials are not allowed; human studies/clinical research are permitted.

pre-application submission is required; application submission is by invitation only.

ida:

• ·     the maximum allowable funding for the entire period of performance is $500,000 for direct costs.
• ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·     the maximum period of performance is 3 years.

ida- career development option:

• ·     the maximum allowable funding for the entire period of performance is $300,000 for direct costs.
• ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·     the maximum period of performance is 3 years.

therapeutic/ diagnostic idea award (tdia) – preproposal due may 26, 2022

tdra: 

independent investigators at or above the level of assistant professor (or equivalent)

tdra – career development option:

• ·     principal investigator (pi) – investigators within 10 years of completing terminal degree at the time of application submission, working to become an independent investigator in tbd research.
• ·     mentor – independent investigators at or above the level of associate professor (or equivalent); must be an experienced tbd researcher as demonstrated by a recent history of funding and publications in tbd research, specifically in the field of the proposed studies.
• ·     mentorship is required.  the pi and mentor may be at different organizations

• ·        treatment and diagnosis focus areas only.
• ·        supports hypothesis-driven therapeutic and diagnostic development research aimed at reducing the burden of lyme disease and/or other tbds and conditions, and improving patient care and/or quality of life.

o treatment-focused applications should be therapeutic evaluation studies designed to promote new ideas aimed at drug or treatment discovery that are still in the early/preclinical stages of development.

o diagnosis-focused applications should propose diagnostic approaches that will be readily integrated into clinical settings.

• ·        research should have translational potential, with proposed studies expected to be empirical in nature and product-driven.
• ·        applicants with limited tbd experience are strongly encouraged to collaborate with experienced tbd investigators.
• ·        applicants with substantial tbd experience are strongly encouraged to partner with experts in therapeutic and diagnostic assay development and transition, particularly those from the commercial sector.
• ·        the career development option is intended to fund early-career investigators to conduct impactful research under the mentorship of an experienced tbd researcher. applications submitted under this option will be reviewed via separate, career development-specific evaluation criteria by a separate, dedicated peer review panel.
• ·        preliminary data is required, unless submitting under the career development option.
• ·        clinical trials are not allowed; human studies/clinical research are permitted.

pre-application submission is required; application submission is by invitation only

tdra:

• ·     the maximum allowable funding for the entire period of performance is $825,000 for direct costs.
• ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·     the maximum period of performance is 3 years.

tdra- career development option:

• ·     the maximum allowable funding for the entire period of performance is $495,000 for direct costs.
• ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·     the maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements that are available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

for email notification when funding opportunities are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the tbdrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

please contact jill sherman, international research facilitator at intl.research@lakeheadu.ca  for additional information.

the fy22 defense appropriations act is anticipated to provide funding for the kcrp to support research of exceptional scientific merit in the area of kidney cancer.  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 kcrp funding opportunity announcements for the following award mechanisms will be posted on the grants.gov website. 

applications submitted to the fy22 kcrp must address one or more of the following focus areas:

• conduct basic biology research to better understand etiology and cancer progression, metastatic disease, refractory disease and therapeutic resistance, genetic and environmental risk factors and the prevention of kidney cancer.
• define the biology of rare kidney cancers and develop treatments to improve outcomes and reduce death.
• identify and develop new strategies for screening, early-stage detection, accurate diagnosis and prognosis prediction of kidney cancers, with examples including biomarkers and imaging.
• develop novel therapeutic strategies for the treatment of kidney cancer, such as novel drug targets, therapeutic modalities and agents, treatment combinations, and drug delivery systems.
• identify and implement strategies to improve the quality of life and survivorship for patients.
• identify and implement strategies to mitigate health disparities, such as access to healthcare, social and cultural factors, environmental factors, and biological contributors.
• support preparation and development of the next generation of kidney cancer researchers, or cultivate collaborations in kidney cancer research or patient care in alignment with the kcrp overarching strategic goals.

funding opportunities - fy22 kidney cancer research program, congressionally directed medical research programs (cdmrp) (army.mil)

concept award – letter of intent due june 23, 2022

all investigators at or above the level of postdoctoral fellow (or equivalent) are eligible

supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.

• ·      emphasis on innovation.
• ·      funding for clinical trials not allowed.
• ·      preliminary data not allowed and should not be discussed.
• ·      blinded review.
  • ·     maximum funding of $100,000 for direct costs (plus indirect costs).
  • ·     maximum period of performance 1 year.

idea development award modified for fy22 – preproposal due june 2, 2022

established investigators: 

independent investigators at or above the level of assistant professor (or equivalent) and 10 years or more from a terminal degree.

early-career investigators:

investigators at the level of assistant professor, instructor, or assistant research professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency/fellowship or family medical leave) at the time of application submission deadline.

• ·      supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.
• ·      preliminary data required.
• ·      innovation and impact are the most important review criteria.
• ·      funding for clinical trials not allowed.
• ·      different funding options, based on the scope of research are available with compelling justification. 

• maximum funding of $675,000 in direct costs (plus indirect costs).

• period of performance not to exceed 3 years.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

postdoctoral and clinical fellowship award – letter of intent due june 23, 2022

must have completed requirements for a ph.d. and/or m.d.

must be in the laboratory or clinical setting where proposed research will be performed.

must have no more than 4 years of postdoctoral and/or mentored clinical research experience.

investigators in non-postdoctoral and/or clinical fellow positions are not eligible.

supports research opportunities focused on kidney cancer for individuals in the early stages of their careers.

• a designated mentor who is an experienced kidney cancer researcher is required.

• clinical trials are not allowed.

• maximum funding of $195,000 for direct costs (plus indirect costs).

• maximum period of performance is 3 years.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

translational research partnership award – preproposal due june 2, 2022

the initiating principal investigator (pi) must be at or above the level of assistant professor or equivalent.

the partnering pi must be at or above the level of assistant professor or equivalent.

• ·      postdoctoral fellows are not eligible to be partnering pis. .

• supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.

• supports translational correlative studies.

• preliminary data are required.

• clinical trials are not allowed.

• maximum funding of $750,000 for direct costs (plus indirect costs).

• maximum period of performance is 3 years.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the kcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

please contact jill sherman, international research facilitator at intl.research@lakeheadu.ca  for additional information.

the fy22 defense appropriations act is anticipated to provide funding for the prorp to support high-impact, clinically relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries. the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 prorp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

applications submitted to the fy22 prorp must address one or more of the following focus areas:

• compartment syndrome and/or reperfusion injury:  novel treatment strategies to improve current diagnoses for compartment syndrome and/or reperfusion injury.  proposals that address the novel treatment strategies to improve the management of reperfusion injury will be considered.  alternatives to intracompartmental pressure measurements are encouraged.
• composite tissue regeneration:  advanced tissue regeneration therapeutics in composite tissue for the restoration of traumatically injured extremities.  isolated bone, cartilage, muscle, or nerve tissue engineering studies are excluded.  techniques aimed at improving outcomes following high-energy extremity trauma, with a focus on improving wound healing and neuromuscular recovery following composite tissue loss and segmental bone loss, are encouraged.
• limb stabilization and protection:  development and/or clinical evaluation of rapid limb stabilization and novel wound protectants for severely or critically wounded limbs to enable prolonged care and eventual transport to the point of definitive treatment.

• ·        osseointegration:  identification of best practices to address infection, rejection, and/or failure of percutaneous osseointegrated prosthetic limbs.
• ·        prostheses and orthoses:  development of high-performance novel prosthetic or orthotic devices designed to enhance whole-person performance and decrease pain in patients with amputation and limb salvage and impairment.  multicenter studies that focus on transfemoral amputees are encouraged, as are advanced limb orthoses that span at least one major joint (i.e., ankle, knee, and elbow).
• ·        retention strategies:  development, optimization, and/or validation of battlefield-feasible diagnostic capabilities, decision support tools, interventions, and/or rehabilitation strategies that can facilitate retention on duty or avoid reinjury for common combat-related musculoskeletal injuries.  biomarker studies are excluded.  the current standard of care must be noted.  the rehabilitation strategy to be used in the proposed study must be specified, as applicable.

a. battlefield care:  strategies that can be utilized at or near the point of injury to allow an injured service member to remain on the battlefield or on mission without the need for evacuation.  development of novel nerve, soft tissue, muscle, and/or skeletal diagnostic capabilities at the point of injury (near battlefield) for diagnosis of underlying pathology and efficacy of interventions.  treatment strategies that allow return to mission effectiveness within 30 days will be considered.

b. return to duty:  treatment strategies that can be utilized along the continuum of care and enable return to duty of the service member within 1 year of injury.

• ·        tissue regeneration therapeutics:  advanced tissue regeneration therapeutics in nerve, muscle, and/or composite tissue for the restoration of traumatically injured extremities.  isolated bone or cartilage tissue engineering studies are excluded.  early clinical feasibility studies involving volumetric muscle loss are encouraged.

• translation of early findings:  translation of early research findings in the orthopaedic surgical care topic areas listed below to move the research toward clinical trials and clinical practice.

a. soft tissue trauma:  strategies to develop and/or identify musculoskeletal extremity soft tissue trauma treatments for shoulder, knee, or chronic ankle instability and sequela only to optimize return to duty, work, or reintegration.

b. fracture-related infection:  strategies to decrease the burden of fracture-related infections (may include prevention, early detection, or improved eradication).  alternatives to systemic antibiotic delivery are encouraged.  novel approaches that improve the current standard of treatment to prevent fracture-related infections are encouraged.

funding opportunities-fy22 prorp, congressionally directed medical research programs (cdmrp) (army.mil)

applied research award – preproposal due june 16, 2022

independent investigators at all academic levels (or equivalent) are eligible to submit applications.

clinical trial award – preproposal due june 16, 2022

independent investigators at all academic levels (or equivalent) are eligible to submit applications.

clinical translational research award – preproposal due june 16, 2022

independent investigators at all academic levels (or equivalent) are eligible to submit applications.

supports high-impact and/or new/emerging clinical research that may or may not be ready for a full-scale randomized controlled clinical trial.

• funding must support clinical research studies involving humans.

• preliminary data relevant to the proposed research project are required.

• investigational new drug or investigational device exemption applications, if needed, should be submitted to the food and drug administration or relevant national regulatory agency within 12 months of the award date.

• applications must address one of the following fy22 prorp ctra focus areas:

○ retention strategies − battlefield care

− return to duty

○ tissue regeneration therapeutics

○ compartment syndrome and/or reperfusion injury

○ osseointegration

○ prostheses and orthoses

• pre-application submission is required; application submission is by invitation only.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prorp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

please contact jill sherman, international research facilitator at intl.research@lakeheadu.ca  for additional information.

the fy22 defense appropriations act is anticipated to provide funding to the department of defense nfrp to support innovative, high-impact nf research.  the managing agent for the anticipated funding opportunities is the congressionally directed medical research programs at the u.s. army medical research and development command.

the fy22 nfrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

applications submitted to the fy22 nfrp must address one or more of the following areas of emphasis:

• neurofibromatosis (nf) type 2-related areas (e.g., hearing, balance, ependymoma, meningioma)
• biomarker discovery, utility, development, and validation
• non-tumor manifestations not limited to:

o   pain

o   cognitive manifestations

o   sleep

• ·        heterogeneity of nf-related tumors
• ·        novel disease and treatment response markers using genetics, genomics, epigenetics, systems biology, metabolomics, or similar approaches
• ·        preclinical efficacy studies
• ·        target identification, drug discovery
• ·        nutritional, environmental, and other modifiers of nf
• ·        health services research

funding opportunities-fy21 nfrp, congressionally directed medical research programs (cdmrp), us dod (army.mil)

clinical trial award – letter of intent due june 20, 2022

must be at or above the level of assistant professor (or equivalent).

• ·      supports research with the potential to have a major impact on the treatment or management of nf.
• ·      funds phase 0, 1, or 2 clinical trials relevant to nf and/or schwannomatosis. combinations of phases are permitted.
• ·      must support a clinical trial and may not be used for preclinical research studies.
• ·     the maximum period of performance is 4 years.
• ·     the maximum allowable funding for the entire period of performance is $800,000 in direct costs ($1,000,000 in direct costs if requesting the qualified organizational collaboration option).
• ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

exploration – hypothesis development award – letter of intent due june 30, 2022

• ·      supports the initial exploration of innovative, high-risk, high-gain concepts and potentially groundbreaking concepts in nf research.
• ·      preliminary and/or published data are encouraged but not required.
• ·      clinical trials are not allowed.
• ·     the maximum period of performance is 2 years.
• ·     the maximum allowable funding for the entire period of performance is $100,000 in direct costs.
• ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

investigator-initiated research award – letter of intent due june 30, 2022

must be either:

• ·     early-stage investigator (esi) - an independent investigator at or below the level of assistant professor (or equivalent) who plans to commit at least 30% of their effort toward the proposed research project; or
• ·     established investigator (ei) - an independent investigator in an area other than neurofibromatosis (nf) at or above the level of assistant professor seeking to transition into a career in nf research who plans to commit at least 10% of their effort toward the proposed research project.

applicants may not have received more than $300,000 in direct costs for nf research as a principal investigator of any program within cdmrp.

new investigator award – letter of intent due june 30, 2022

early-stage investigator (esi):  an independent investigator at or below the level of assistant professor (or equivalent) and commit at least 30% during each budget year of their efforts toward the proposed nf research project.

established investigator (ei): an independent investigator above the level of assistant professor and commit at least 10% during each budget year of their efforts toward the proposed nf research project.

• ·      esi:  supports the continued development of promising independent investigators
• ·      ei:  supports the transition of established investigators from other research fields into a career in nf research.
• ·      prior experience in nf research is not required.
• ·      preliminary and/or published data relevant to nf and the proposed research project are required.
• ·      clinical trials are not allowed.
• ·     the maximum period of performance is 3 years.
• ·     the maximum allowable funding for the entire period of performance is $450,000 in direct costs.
• ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

early investigator research award – letter of intent due june 30, 2022

the investigator must:

• ·     be involved in a postdoctoral training or medical residency program;
• ·     possess up to 4 years of continuous postdoctoral research experience by application submission deadline; and
• ·     possess a doctoral degree (i.e., ph.d., m.d./ph.d., d.o./ph.d.) or a clinical doctoral degree (i.e., m.d./d.o. or ph.d. in a clinical discipline) from an accredited organization or program.  must commit at least 50% of effort to the project.
• ·      supports nf-focused research opportunities for individuals in the early stages of their careers.
• ·      investigators must have a designated mentor who is an experienced nf researcher.
• ·     the maximum period of performance is 2 years.
• ·     the maximum allowable funding for the entire period of performance is $200,000 in direct costs.
  • ·      indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

synergistic idea award

must be an investigator at or above the level of assistant professor (or equivalent) who plans to commit at least a 10% level of effort for each budget period throughout the entirety of the award.

• ·      supports new ideas that represent synergistic approaches involving two or three principal investigators (pis) (initiating pis and pi[s]) to address a central problem or question in nf research.
• ·      preliminary and/or published data are required.
• ·      clinical trials are not allowed
• ·     the maximum period of performance is 3 years.
• ·     the maximum allowable funding for the entire period of performance is $2,000,000 in direct costs.
• ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other u.s. army medical research and development command extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the nfrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

please contact jill sherman, international research facilitator at intl.research@lakeheadu.ca  for additional information.

the fy22 defense appropriations act is anticipated to provide funding for the jwmrp to augment and accelerate high-priority department of defense (dod) and service medical requirements through the continuation of dod core and congressionally directed prior year research and development initiatives that are close to achieving their objectives and yielding a benefit to military medicine.  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 jwmrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

the mission of the jwmrp is to accelerate research and development projects that have the potential to close high-priority dod medical requirements and capability gaps.  within this context, the jwmrp is interested in supporting research and development efforts that address overarching and service-specific priorities; therefore, applications are required to address one or more of the following fy22 jwmrp focus areas:

• ·        endemic and emerging disease threats

○       preventative measures for infectious diseases, including combat wound care in austere and prolonged field care environments

○       therapeutic measures for infectious diseases, including combat wound care in austere and prolonged field care environments

○       capabilities to support conducting real-time research during the response to identify and characterize emerging biothreats and develop unique and pan-pathogen response tools in order to improve response and recovery and enhance capabilities to conduct clinical research at the onset of a bio-incident

• ·        operational medicine and readiness

○       research aimed toward injury prevention, rapid return-to-duty capabilities, and rehabilitation solutions to maintain service member readiness (musculoskeletal and neurosensory)

○       artificial intelligence/machine learning and biotechnology applications to enhance health and medical surveillance critical to identifying biothreats and bio-incidents, impacts from climate and environmental change, and exposures to chemicals and physical stressors in military operations

○       tools and technologies (e.g., digital phenotyping with wearable technologies) to improve detection, prevention, and treatment for behavioral health conditions

○       mechanism-based criteria and injury prediction models for ballistic and/or blast-induced head injuries from a wide range of loading regimes seen with current and likely future weapons systems, with the goal of informing the development of more effective helmet protection

• ·        environmental medicine

○       metrics/measures to determine service member environmental susceptibilities and enhance service member health and performance in operational extremes (environmental/climatic), particularly arctic, high altitude, or surface/undersea conditions

• ·        combat casualty care

○       modernized combat casualty care capabilities that can deliver life-saving care at the point of injury, enable prolonged casualty care, provide advanced resuscitative and damage control surgical care, and long-distance en route care consistent with the demands of an all domain battlespace against a near peer competitor:

–        tools that enhance medical decision-making capabilities and reduce cognitive burden on medical providers and warfighters (e.g., artificial intelligence-based clinical decision support, augmented reality systems, procedural telementoring capabilities)

–        autonomous care and evacuation capabilities that augment the individual medic/warfighter or system in order to increase the capability and capacity for casualty response

–        novel solutions for non-compressible torso hemorrhage

–        intelligent imaging technologies that provide increased diagnostic capability in the forward operating environment, particularly those that can identify life-threatening hemorrhage or neurologic injuries or facilitate early return to duty for less severe injuries

–        solutions to enhance the provision of combat casualty care (including tactical combat casualty care, en route care, and damage control surgery) in extreme cold weather environments

–        solutions that improve the combat casualty care system’s ability to manage large numbers of casualties including improved triage, medical regulating, and evacuation capabilities

○       validated training platforms for the acquisition and retention of knowledge, skills, and abilities aligned to wartime medical specialties of the operational force while refining, reducing, and replacing use of live tissue

funding opportunities-fy22 joint warfighter medical research program, congressionally directed medical research programs (cdmrp) (army.mil)

military medical research and development award – preproposal due may 16, 2022

extramural and intramural applicants

independent investigators at all academic levels (or equivalent)

• ·        pre-application is required; application submission is by invitation only.
• ·  applicants must have already received dod core or dod congressionally-directed prior year funding for the same research and/or development project being proposed for logical continuation under this funding opportunity
• ·  funds shall not be used for new projects or for basic research
• ·  supports a wide range of research projects, spanning preclinical studies, translational and technology development, clinical studies (including correlative studies and initial safety and efficacy testing of promising drug and vaccine candidates, medical devices, and technologies), and all phases of clinical trials
  • ·        must address at least one of the fy22 jwmrp focus areas
  • ·        maximum funding of $4.5 million for total costs (direct plus indirect costs)
  • ·        maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

for email notification when funding opportunities are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the jwmrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

for more information, please contact jill sherman, international research facilitator at intl.research@lakeheadu.ca